30
Views
22
CrossRef citations to date
0
Altmetric
Research Article

Dosage Recommendations for Activated Charcoal-Sorbitol Treatment

, &
Pages 579-587 | Published online: 25 Sep 2008

References

  • Kullg K, Bar-Or D, Cantr SV, III, Rosen P, Rumack BH. Management of acutely poisoned patients without gastric emptying. Ann Emerq Med. 1985; 14: 562–567
  • Krenzelok EP. Gastric transit times of cathartics used with activated charcoal. Clin Pharm. 1985; 4: 446–448
  • Minocha A, Herold DA, Bruns DE, Spyker DA. Effect of activated charcoal sorbitol mixture In healthy Individuals. Clin Toxicol. 1985; 22: 529–536
  • Agostlnl L, Down PF, Murlson J, Wrong OM. Faecal ammonia and pH during lactulose administration In man: comparison with other cathartics 1972; 13(11)859–866
  • Krenzelok EP, Keller R, Stewart RD. Elimination of activated charcoal with cathartics. Ann Emerg Med. 1985, In press
  • Pond SM, Olson KR, Oster I, Oh JD, Tong TG. Randomised study of the treatmentbof phenobarbltal overdose with repeated dose of activated charcoal. JAMA 1984; 251: 3104–3108
  • Kasper L, Irslgler K. A comparison of blood glucose Increase and insulin requirement after oral sucrose, fructose and sorbitol alone or In combination. Weln-Klin-Wochencher 1980; 22: 683–687
  • Anderson CC, Shahvarl MBG, Zimmerman JE. The treatment of pulmonary edema In the absence of renal function. JAMA 1979; 241: 1008–1010
  • Picchloni AL, Chin L, Gilesple T. Evaulation of activated charcoal-sorbitol suspension as an antidote. J Toxicol: Clin Toxicol. 1982; 12: 433–444
  • Willame Graff VD, Thompson WL, Sunshine I, Fretthol DD, Lelckly F, Dayton H. Adsorbent and Cathartic Inhibition of Enteral Drug Absorption. J Pharmacol Exp Thera. 1982; 221: 656–663
  • Smith RP, Gosselin RE, Henderson JA, Anderson DM. Comparison of the adsorptlve properties of activated charcoal and alaskan montmortllonite for some common poisons. Toxicol App I Pharmacol. 1967; 10: 95–104
  • Chin L, Plechionl AL, Bourn WM, Laird HE. Optimal antidotal dose of activated charcoal. Toxicol AppI Pharmacol. 1973; 26: 103–108

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.